877 ROLE OF STEROID HORMONE RECEPTORS ON FORMATION AND PROGRESSION OF BLADDER CARCINOMA

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research1 Apr 2011877 ROLE OF STEROID HORMONE RECEPTORS ON FORMATION AND PROGRESSION OF BLADDER CARCINOMA Gholamreza Pourmand, Sepehr Salem, Abdolrasoul Mehrsai, and Farid Kosari Gholamreza PourmandGholamreza Pourmand Tehran, Iran More articles by this author , Sepehr SalemSepehr Salem Tehran, Iran More articles by this author , Abdolrasoul MehrsaiAbdolrasoul Mehrsai Tehran, Iran More articles by this author , and Farid KosariFarid Kosari Tehran, Iran More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.701AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Steroid hormone receptors expression, including estrogen (ER), progesterone (PR) and androgen (AR) play essential roles in development, growth, tumorigenesis, and progression of several malignancies; however, there is limited experience with urothelial carcinoma of the bladder (UCB), especially regarding prognostic and therapeutic impact. Furthermore, males have a substantially higher risk of developing UCB than females, whereas its etiology still remains largely obscure. This study sought to further clarify the role of ER/PR/AR expression in UCB, and also to evaluate the possible associations with progression and survival of cancer. METHODS 120 patients with clinicopathologically confirmed primary UCB, and 132 controls without any malignant disease were evaluated prospectively. Their pathologic specimens were stained immunohistochemically using avidin-biotin-peroxidase technique and monoclonal ER/PR/AR antibodies were used to determine the ER/PR/AR expression (Dako). Staining characteristics were compared with the clinic-pathological results. Cox regression was used to estimate the adjusted hazard ratios (HR) with 95% confidence intervals (CI), and impact on disease-free survival was analyzed using Kaplan-Meier method. RESULTS ER/PR expressions were observed in 4.2%/2.5% of cases and 2.3%/1.5% of controls. AR expression was detected in 22% of the patients and all controls were AR-negative. No significant association was found between ER/PR immunoreactive scores and age, tumor size, stage and grade, while statistically significant correlation was revealed between AR expression and tumor stage and grade. AR/PR-positive patients had higher rate of metastasis in comparison with AR/PR-negative patients (p<0.05). In multivariate regression analysis, ER/PR was not found to be independent prognostic factors and survival was not affected by their expressions. However, AR-positive patients showed a significantly poorer prognosis than AR-negative cases (log-rank test, p=0.02) and it could also be used as a prognostic factor (HR: 2.12; 95%CI: 1.36–4.65). CONCLUSIONS AR expression was found in almost 22% of the tumors and it was significantly associated with high stage, poorly differentiated tumors and unfavorable outcome. Hence, AR could be considered as a potential target for additional hormonal therapy. AR evaluation test could also be regarded as a diagnostic procedure for determining the malignant bladder issues. Moreover, ER and PR expression were not found to have any direct roles on formation and progression of UCBs. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e351 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gholamreza Pourmand Tehran, Iran More articles by this author Sepehr Salem Tehran, Iran More articles by this author Abdolrasoul Mehrsai Tehran, Iran More articles by this author Farid Kosari Tehran, Iran More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...